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Live attenuated vaccines to prevent varicella and zoster have been available in the US for the past 17
years, with a resultant dramatic decrease in varicella incidence and a predicted future decrease in the
incidence of zoster. The pathogenesis and immune responses to varicella zoster virus (VZV) as well as
the safety and effectiveness of VZV vaccines are reviewed. The lack of sterilizing immunity provided by
VZV vaccines has not prevented them from being safe and effective. Virological and pathological
information concerning parallels and differences between VZV and herpes simplex virus (HSV) are
highlighted. Although VZV and HSV are distinct pathogens, they appear to have similarities in target
organs and immunity that provide an expectation of a high likelihood for the success of vaccination
against HSV, and predicted to be similar to that of VZV.
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For many years, varicella zoster virus (VZV) and herpes simplex
virus (HSV) were thought to be such similar viruses that it was
almost unnecessary to study each of them; research on HSV would
mostly sufﬁce for both viruses. HSV was recognized to have the
great advantage of being easier to propagate than VZV, so it was
‘‘chosen’’ as the reference virus. In 1989, however, Straus enumer-
ated several critical biological and clinical differences between the
two pathogens (Straus, 1989). These included characteristics of
latent infection and reactivation, such as numbers of skin lesions
and frequency of recurrences, and pain symptoms. After that time,
it began to be appreciated that VZV deserved study on its own.
Today it is clear that while these herpesviruses may look alike, they
are different in many aspects. Perhaps the most important differencell rights reserved.is that safe and effective live attenuated vaccines were developed for
VZV: against varicella in 1974 (Takahashi et al., 1974), and against
herpes zoster (HZ) in 2005 (Oxman et al., 2005). Because of the
absence of suitable animal models for varicella disease, it was
necessary to carry out even the earliest tests of vaccine efﬁcacy
directly in humans, although safety testing was ﬁrst performed in
various animals (Takahashi et al., 1974). Effective vaccines against
HSV, however, remain elusive.
Usually VZV does not cause severe illness. However a number of
complications are associated with this virus, including those invol-
ving the respiratory (pneumonia) and nervous systems (meningitis,
encephalitis, vascuopathy/stroke, retina), and the skin (Gilden et al.,
2010).
VZV vaccines were licensed for routine use against varicella in the
United States in 1995 (Centers-for-Disease-Control, 1996), and
against HZ in 2006 (Mitka, 2006). They have been extremely effective
in preventing both diseases (Gershon and Gershon, 2010; Hambleton
et al., 2008; Hardy et al., 1991; Marin et al., 2011; Oxman et al., 2005;
Shapiro et al., 2011).
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Pathogenesis. VZV is spread via the airborne route (Gustafson
et al., 1982,Leclair et al., 1980). Although it was assumed for years
that VZV spreads from the respiratory tract of infected individuals,
evidence for this is minimal (Brunell, 1989; Gold, 1966). The main
route of spread appears to be aerosolization of cell free VZV present
in vesicular skin lesions in both varicella (primary infection) and HZ
(secondary infection due to reactivation of VZV from latency) (Chen
et al., 2004; Tsolia et al., 1990). Infectious VZV is carried in CD4þ
and CD8þ T lymphocytes during viremia (Arvin et al., 2010) and
seems to spread primarily from one cell to another without exiting
into the extracellular space (Weller, 1983), with exceptions invol-
ving the superﬁcial layer of the skin and T lymphocytes. Mostly, VZV
exists as an intracellular pathogen, which may explain why cell
mediated immunity (CMI) rather than antibody is critical for host
defense.
VZV is cell-associated because N-linked glycoproteins of its
envelope contain exposed mannose-6 phosphate (Man 6 P) moieties
(Gabel et al., 1989), which enable the virus to bind to Man 6 P
receptors (MPRs). When VZV is enveloped in the trans-Golgi net-
work, therefore, newly enveloped virions follow the itinerary of
MPRs and trafﬁc to late endosomes, within which the environment
is acidic and VZV is inactivated. Subsequent exocytosis is of non-
infectious viral particles. Cell-to-cell spread, which involves fusion of
infected cells with neighbors, thus becomes the main means by
which VZV can infect naive cells in vitro. In skin lesions, however,
VZV-infected cells secrete fully infectious varicella virions into the
extracellular space. They are able to do this because MPR expression
is shut down as suprabasal cells of the epidermis mature into
squames; therefore, infected suprabasal epidermal cells do not
divert newly enveloped VZV to acidic endosomes, but instead
package virions in secretory vesicles that carry it to the plasma
membrane for exocytosis (Chen et al., 2004). When VZV initially
contacts the respiratory mucosa of a susceptible individual, there-
fore, it arrives as a cell-free virion; during this time antibodies,
delivered by passive immunization can prevent or modify infection
(Gershon, Steinberg, and Brunell, 1974).
In establishing latency, VZV may be directly transferred from
skin lesions to neuronal cell bodies via axons projecting to
infected areas, by the process of retrograde axonal transport. In
addition, infected T cells may pass VZV to neurons during T cell
viremia, although it is not clear exactly how this transfer is
accomplished. Spread of VZV to neurons by viremia was also
demonstrated in simian varicella virus (Ouwendijk et al., 2012b).
T cells may release cell free virions (Moffat et al., 1995) or may
release VZV in exosomes, which fuse with neurons. Electron micro-
graphs of lymphocytes infected with VZV suggest that virions may
not be inactivated within endosomes but are well formed and
packaged individually in secretory vesicles, as seen in suprabasal
epidermal cells (Chen et al., 2011).
Varicella has an average incubation period of 2 weeks; during
this time innate immunity protects the skin from the viremic
phase of the illness, but eventually the virus overcomes this
immune response. At that point, however the adaptive immune
system is activated in host defense (Ku et al., 2005; Ku et al.,
2004). In addition, the transfer of VZV from one infected cell to
another cell probably contributes to slow viral replication, which
might be important in host survival (Chen et al., 2004). It seems
likely that the rather long incubation period may enable disease
prevention by vaccination. Although VZV has capabilities to effect
immune evasion, this phenomenon seems not to be as well
developed as it is for HSV (Abendroth and Arvin, 2001; Johnston
et al., 2011; Laing et al.; Peng et al., 2009).
Immunity to VZV. There is only one serotype of VZV, although
there are at least 7 viral clades, which have been identiﬁed fromdifferent geographic areas of the world (Breuer et al., 2010).
Nevertheless, natural infection with VZV provides life-long pro-
tection against a second attack of varicella in most people; second
attacks are unusual or rare (Gershon et al., 1984a; Junker, Angus,
and Thomas, 1991). Almost simultaneously with the development
of the live attenuated vaccine against varicella (Oka strain)
(Takahashi et al., 1974), a sensitive and speciﬁc serologic test for
VZV antibodies was described (Williams et al., 1974). Over time,
this assay, the ﬂuorescent antibody to membrane antigen (FAMA)
test has proven to be an excellent indicator of protective immunity
to varicella (Gershon et al., 2007; Gershon et al., 1984b; Michalik
et al., 2008). Our laboratory has tested and followed numerous
individuals who have undergone FAMA testing. Of persons with a
FAMA titer of Z1: 4 (n¼131), fewer than 2% developed varicella
after a household exposure to VZV; by contrast, the attack rate
after household exposure in individuals with a titer of o1:4 was
59% (n¼68) (Michalik et al., 2008). The availability of the FAMA
test as a correlate of immunity, and the high attack rate of varicella
following exposure to VZV among susceptibles were extremely
helpful in the early evaluation of the efﬁcacy of varicella vaccine
(Asano et al., 1983, 1994; Gershon et al., 1984b). ELISA testing
proved to be less useful regarding protection from illness, although
early results showed seroconversion rates over 90% following one
dose of vaccine (Gershon et al., 2012).
Latency and reactivation of VZV. VZV becomes latent in the
dorsal root ganglia (DRG), cranial nerve ganglia (CNG) and enteric
ganglia (EG) following chickenpox and vaccination. In contrast to
latency with HSV, during latent VZV infection, transcripts and
proteins of at least 6 of the 71 viral genes are expressed in
neurons harboring latent VZV (Chen et al., 2011; Gershon et al.,
2012; Kennedy and Cohrs, 2011).
Abundant clinical evidence indicates that some aspect of CMI is
involved in preventing VZV reactivation disease (Arvin et al., 1978;
Hardy et al., 1991). Exactly what controls VZV reactivation itself
remains unclear. In contrast to HSV, inﬁltrating T cells are not found
surrounding neurons that are infected with VZV (Verjans et al.,
2007). The incidence of HZ begins to increase in individuals at the
age of 50, at the same time that CMI to VZV begins to decrease
(Berger et al., 2000; Burke et al., 1982). Presumably this loss of CMI
is due to immunoscenescence secondary to aging. Immunocompro-
mised patients are also at increased risk to develop HZ compared to
healthy persons of the same age (Cohen et al., 2007). Children and
adolescents who develop HZ may have transient decreases in CMI to
VZV, possibly due to preceding viral infections that were asympto-
matic, or to stress (Mehta et al., 2004).
In addition to being latent in CNG and DRG, RNA transcripts of
wild type (WT) and Oka VZV and associated proteins have been
demonstrated in enteric neurons in fresh surgical specimens
removed from the intestines of children and adults (Chen et al.,
2011). The demonstration of latency of VZV in EG is important
because reactivation in intestinal ganglia may lead to a number of
gastrointestinal diseases ascribed to VZV, such as achalasia,
gastric ulcers, and colonic pseudoobstruction, also known as
Oglivie’s syndrome (Castex et al., 1995; Edelman et al., 2009;
Pui et al., 2001; Roberetson et al., 1993; Stratman, 2002; Ussery
et al., 1998). With the identiﬁcation of latency of VZV in the ENS,
and the potential for reactivation there, the pathogenesis of
gastrointestinal disease due to VZV becomes clearer. Both WT
and the Oka strain become latent in the ENS (Chen et al., 2011).
We recently identiﬁed an adolescent male with a severe gastric
ulcer caused by Oka VZV, which must have been due to reactiva-
tion from latency, following 2 doses of varicella vaccine (Cohrs
and Gilden, 2012). The demonstration of VZV RNA transcripts in
fresh intestinal neuronal tissues (Chen et al., 2011) avoids the
confounding possibility of reactivation of VZV after death in
autopsy specimens (Ouwendijk et al., 2012a). The molecular
Table 1
Latent VZV (DNA/RNA) was found by PCR in ganglia at multiple levels, often
bilaterally. Distribution of VZV DNA/RNA in ganglia of vaccinated patients.
Source: Gershon et al. (2012).
Patient
Age
Vaccinated Trigeminal Cervical Thoracic Lumbar Type
Right Left Right Left Right Left Right Left
1.75 Yes 0 0 0 0 0 þ þ 0 Oka
2 Yes 0 0 0 0 þ 0 þ 0 Wild
2 ? þ þ 0 0 þ 0 0 þ Wild
2 Yes þ þ þ þ þ þ þ þ Wild
4 Yes 0 0 þ þ þ þ þ 0 Wild
8 Yes 0 0 0 0 þ 0 0 0 Wild
10 Yes þ þ 0 0 þ 0 þ 0 Wild
DNA examined: ORFs 4, 31, 63, 66, 67; RNA examined: ORFs 4, 40, 63, 66.
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an important aspect of studies on recipients of varicella vaccine in
documenting reactivation and reinfection (Gershon et al., 1984b;
LaRussa et al., 1992; Quinlivan et al., 2012).
Reactivation of VZV can occur following stress (Cohrs and Gilden,
2012; Mehta et al., 2004; Schmader et al., 1990). Following space
travel, 30% of astronauts developed asymptomatic reactivation of
VZV, manifested by the transient appearance of VZV DNA in their
saliva (Mehta et al., 2004). On occasion infectious VZV was also
found in saliva, but this shedding is probably quite rare and has not
been associated with viral transmission (Cohrs et al., 2008). VZV
reactivation usually presents with rash, but rash may not invariably
occur (Cohrs and Gilden, 2012; Gilden et al., 2010, 1994). When
there is no rash, the virus may be demonstrated by the presence of
VZV DNA in saliva (Cohrs and Gilden, 2012) or cerebrospinal ﬂuid
(CSF) (Gilden et al., 2010).Selected aspects of Immunization with live attenuated varicella
vaccine
Varicella vaccine. Live attenuated varicella vaccine is licensed for
routine use in many countries in the world. Originally, in the United
States, one dose was recommended for children (Centers-for-
Disease-Control, 1996). Due to failure of seroconversion after 1 dose
in roughly 20% of children, shown by FAMA testing (Michalik et al.,
2008), and also due to continuing outbreaks of varicella in day care
facilities and schools (Gershon et al., 2012), a two dose regimen was
recommended by the Centers for Disease Control and Prevention
(CDC) in 2006 (Centers-for-Disease-Control, 2007a). One dose of
vaccine was shown to protect roughly 85% of children (Shapiro et al.,
2011; Vazquez et al., 2001); this increased to 98% protection after a
second dose was administered (Shapiro et al., 2011). There appears
to be little laboratory documented loss of immunity with time even
after receipt of only 1 dose (Vazquez et al., 2004). Although one
study purported to showwaning immunity to varicella, its validity is
unproven because diagnoses were made only on clinical grounds,
and primary vaccine failure was not taken into account (Chaves
et al., 2007).
Development of clinical HZ following varicella vaccination is
signiﬁcanty lower than after natural infection in immunocom-
promised and healthy vaccinees (Hardy et al., 1991; Son et al.,
2010; Tseng et al., 2009). The rate in vaccinated adults is
extremely low, 0.9/1000 person-years of observation, which is
also less than would be seen after natural infection (Hambleton
et al., 2008). The reported rate in healthy vaccinated children is
0.33/1000 person-years, which may be as much as 10 times lower
than would be expected after natural varicella (Tseng et al., 2009).
After varicella vaccination of HIV-infected children, no cases of HZ
were observed (Son et al., 2010).
Interestingly, WT VZV rather than the Oka strain is the cause of
HZ in about 1/3 of vaccinated children who develop this illness
(Galea et al., 2008; Vazquez, 2012). This is may be the result of
asymptomatic VZV viremia occurring after exposure to WT VZV;
most of these children have had no history of breakthrough
varicella. Usually HZ in vaccinees is not serious, although there
appears to be no difference in severity of the illness between Oka
and WT (Vazquez, 2012). In autopsy studies of children who
received 1 dose of Oka vaccine who subsequently died suddenly
in accidents, studies of sensory ganglia revealed widespread
latency with WT VZV (Gershon et al., 2012). None of the autopsied
children had experienced varicella or HZ. Possibly they developed
a subclinical VZV WT viremia upon exposure to WT VZV, but the
viral burden was low and no reactivation was observed during the
lifetimes of the children (Gershon et al., 2012) (Table 1). It is
impossible to know if this infection occurred before or aftervaccination, but in any case it was subclinical. Presumably at
least some children were infected with WT after vaccination.
Prior to widespread vaccination in the United States, there
were about 100 annual deaths from varicella, mostly in otherwise
healthy children and adults. Today, not only has the incidence of
varicella declined dramatically but also the rate of hospitaliza-
tions from this disease has fallen, and deaths from varicella in the
years between 1995–2007, have become rare (Marin et al., 2008,
2011). (Fig. 1) These encouraging data were obtained during the
period when only 1 dose of varicella vaccine was given; pre-
sumably the situation will improve even further now that 2 doses
are routinely given.
There is ample evidence that universal deployment of live
attenuated varicella vaccine has decreased transmission of VZV in
the U.S. As mentioned, there are now fewer hospitalizations,
fatalities, and reported outbreaks of varicella in schools. In is
unusual to see patients with varicella today, and young American
clinicians have little or no experience in managing this infection.
The decrease in VZV transmission has occurred despite observa-
tions that sterilizing immunity has not always been achieved by
vaccination. The vaccine commonly protects against disease but
reinfections and viral latency have not entirely disappeared. As
seen in Table 1, silent reinfections can occur with accompanying
latency of WT VZV. Latency due to silent WT infection is also
indicated by the observation that in 1/3 of vaccinees who develop
HZ, WT VZV is the cause. The 15% breakthrough infection rate of
mild to moderate (but not severe) varicella after 1 dose is
additional evidence that vaccination does not completely protect
against disease, despite reports of over 90% seroconversion by
ELISA. Data regarding FAMA seroconversions in healthy child
vaccinees are limited, but show that only about 80% of children
seroconvert by this assay, following 1 dose. There are no pub-
lished data regarding seroconversions by FAMA after 2 doses. The
best indications of the efﬁcacy of varicella vaccine come from
studies that have assessed the proportion of exposed vaccinees
who were protected after intimate exposures to the virus (Asano
et al., 1983, 1994; Gershon et al., 1984b, 2012).
Varicella vaccine has been shown to be extremely safe. In
contrast to 100 varicella deaths annually from WT disease in
the pre-vaccine era in the United States, there is only one varicella
death from the Oka strain on record in the world literature, in an
English child with underlying leukemia (Ulloa-Gutierrez, 2007), in
the past 15 years. The most frequently reported adverse reaction
to vaccination is a mild rash that appears several weeks later in
about 5 percent of healthy children, particularly after a ﬁrst
vaccine dose (Chaves et al., 2008; Galea et al., 2008; Gershon
and Gershon, 2010; Gershon et al., 1991, 1988; Sharrar et al.,
2000). Extensive rashes, with occasional pneumonia or neurologic
Fig. 1. Annual age-speciﬁc mortality rates for varicella due to varicella as the underlying cause were reduced 88% by 2004–2007, after introduction of varicella vaccine in 1995.
Based on ﬁgure in Marin et al, 2011.
Table 2
Meningitis caused by the Oka strain of VZV, diagnosed by PCR on CSF in children vaccinated at 1 year of age.
Case Report year Author Medical history ORFs tested Age Location of zoster rash
1 2003 Levin Neuroblastomaa 62 1 yr R. thigh
2 2008 Bryan Neuroblastomaa 62 21b mo hands, R leg, abdomen
3 2008 Galea; Chavez Leukemia chemotherapya 38, 54 4 yr arm
4 2008 Chavez Healthy 38,54 4 yrc R. arm
5 2008 Levin Healthy 38, 54, 62d 8 yr L. shoulder
6 2009 Iyer Healthy 38, 54, 62 9 yr L. arm
7 2010 Chouliaras; Goulleret Healthy 62 3 yr Face e (trigeminal)
8 2011 Han Healthy 38, 54, 62 7 yr. R. arm, shoulder
9 2011 Pahud Healthy 38, 54, 62d 12 yr neck
a healthy when immunized.
b immunized at 20 mo.
c immunized at 32 mos.
d and other ORFs.
e also had encephalitis.
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children who were inadvertently vaccinated, such as those with
undiagnosed AIDS, natural killer (NK) cell deﬁciency, and other
immunodeﬁciency diseases. They have been treated successfully
with antiviral therapy (Gershon, 2003; Jean-Philippe et al., 2007;
Kramer et al., 2001; Levy et al., 2003). There is a potential for
transmission of the vaccine virus if vaccinees develop rash from
the Oka strain, but transmission is extremely rare from healthy
individuals; fewer than 10 instances of transmission have been
reported since 1995, during which time as many as 60 million
children in the United States were vaccinated (Centers-for-
Disease-Control, 2007b; Chaves et al., 2008; Galea et al., 2002;
Sharrar et al., 2000). A few notable neurologic events were related
to varicella vaccine. There are 9 reports of HZ due to the Oka
strain with accompanying meningitis, in which VZV DNA was
found in CSF by polymerase chain reaction (PCR). The patients
were a mixture of healthy and immunocompromised children;
most received antiviral therapy and all recovered (Pahud et al.,
2011). (Table 2) This form of meningitis has also been reported as
being caused by WT VZV (De La Blanchardiere et al., 2000;
Dueland et al., 1991; Gilden et al., 2010; Levin et al., 2008;
Pahud et al., 2011; Spiegel et al., 2010). It is therefore unclear
whether or not these 9 Oka meningitis patients should be
classiﬁed as having a vaccine-associated adverse event. There isno known denominator for meningitis caused by WT or Oka VZV;
therefore the incidence of these complications is not known, but
this illness in vaccinees appears to be rare. Transient cerebellar
ataxia has been reported following vaccination, but its connection
to VZV, if any, has not been proven (Chaves et al., 2008; Galea
et al., 2008; Sharrar et al., 2000).
Zoster vaccine. In addition to the preventive vaccination against
varicella, a therapeutic vaccine was developed to prevent HZ,
composed of the Oka strain of VZV, but at a dose 14 times
greater than that used to prevent varicella. The rationale is to
revive the CMI response to VZV in the aged, and thus to prevent
VZV from reactivating and causing disease. This vaccine is roughly
60% effective in preventing HZ and post herpetic neuralgia in
healthy persons over the age of 60 years (Oxman et al., 2005).
Because of its recently demonstrated safety and efﬁcacy in a
younger age group, it has now been recommended for individuals
over the age of 50 years, in whom it is 70% effective if given
between 50–59 years (Schmader et al., 2012b). A subunit zoster
vaccine composed of adjuvanted glycoprotein E of VZV has been
developed and appears to be highly immunogenic in Phase
2 studies (Leroux-Roels et al., 2012). This vaccine is currently in
Phase 3 clinical trials, but as yet there are no data available
regarding its safety or efﬁcacy. (http://clinicaltrials.gov/ct2/show/
NCT01165203).
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will lead to an increase in the incidence of HZ in the unvaccinated
population has been heatedly discussed (Crumpacker, 2011;
Goldman and King, 2012). Certain investigators proposed that
exposure to WT VZV is essential to maintain long term immunity
to VZV (Thomas et al., 2002), while data of others disputes this
idea (Gaillat et al., 2011). It is clear that the incidence of HZ is
increasing in the United States, but this has been occurring over a
period of more than 50 years (Donahue et al., 1995; Ragozzino
et al., 1982), long before the advent of varicella vaccine. Undoubt-
edly the increase in zoster incidence is multifactorial and includes
increases in ascertainment and diagnosis, as well as increases in
numbers of immunocompromised and elderly individuals, and
possibly increases in other factors such as stress. Whether
vaccination has contributed to this rise in HZ incidence is difﬁcult
to sort out, but varicella vaccination cannot be the only cause
since it was licensed in the United States only in 1995, long after
the increase in incidence began. A computer modeling study
predicted an increase in the incidence of HZ in the vaccine era
that would lead to an epidemic of HZ in the population with 50%
of young and middle-aged adults developing HZ, and 5000 deaths
(Brisson et al., 2002). Clearly this has not happened. The most
recent estimated death rate from HZ in the United States is less
than 100 patients annually (Mahamud et al., 2012).
Another putative mechanism for maintaining long-term immu-
nity to VZV is by subclinical reactivation from latency. This possibility
was suspected years ago (Luby et al., 1977) but could not be ﬁrmly
documented until molecular techniques such as PCR became avail-
able. Now more and more evidence for the occurrence of subclinical
reactivation of VZV is accumulating in immunocompromised and
immunocompetent individuals (Birlea et al., 2011; Cinque et al.,
1997; Ljungman et al., 1986; Mehta et al., 2004; Wilson et al., 1992).
It seems that VZV reactivation has a spectrum ranging from sub-
clinical to zoster without rash or zoster sine herpete (Blumenthal
et al., 2011; Cohrs and Gilden, 2012; Gilden et al., 2010) to localized
unilateral dermatomal vesicular skin lesions, to widespread skin
vesicles with visceral involvement resembling severe varicella.
Why then has the development of varicella vaccine so success-
ful in reducing disease from this infection? The vaccine is clearly
attenuated (Gershon et al., 2012; Tsolia et al., 1990) and very safe,
even in selected immunocompromised patients (Gershon et al.,
1984b; Son et al., 2010). From the beginning of vaccine testing
there was an immune correlate, the FAMA test, which was
immensely helpful in evaluating vaccine efﬁcacy. The Oka strain
has limited transmissibility, and it is susceptible to standard
antiviral drugs (Preblud et al., 1984). While Oka can cause latent
infection, the potential for reactivation disease (HZ) is lower that
for WT VZV. There is the potential to boost immunity for those
whose CMI is waning due to aging with an Oka based vaccine
(Oxman et al., 2005; Schmader et al., 2012a). There is also the
possibility that boosting of immunity may be accomplished by
non-infectious subunit vaccines, which are still under investiga-
tion. (http://clinicaltrials.gov/ct2/show/NCT01165203)
In summary, VZV vaccines have proven remarkably effective
and safe. The incidence of varicella and its complications has
decreased dramatically in the United States by its use. In one study
of unvaccinated HIV-infected children, the incidence of varicella
decreased by over 60% in the post-vaccine era, indicating decreased
viral transmission and herd immunity (Son et al., 2008). Currently
over 90% of young children have been immunized, and hospitaliza-
tions and deaths from varicella have fallen dramatically (Marin et al.,
2011; Shah et al., 2011). Inroads into the conquest of HZ are also
being made, both by varicella vaccine use and the therapeutic
vaccine to prevent HZ. Interestingly, this success with VZV vaccines
has occurred although the vaccines do not achieve the ideal of
‘‘sterilizing’’ immunity. With all of the available approaches, anddespite the vagaries, perhaps it has actually been possible to
improve on Mother Nature with prevention of varicella and zoster
by vaccination.Development of vaccines against HSV
Given that HSV is much easier to propagate and historically at
least to produce mutant viruses than VZV, one might have
predicted that a vaccine for HSV 1 and 2 would have been
developed long before VZV vaccines, but we are still awaiting
the availability of successful vaccines for HSV. Some of the
differences between HSV and VZV might help to explain problems
encountered with vaccine development of HSV. One important
difference between the viruses is in their incubation periods for
causing primary disease; this period is as much as 10 times longer
for VZV than for HSV (Gershon et al., 2012). This phenomenon
probably partially relates to the mode of infection: varicella has a
fairly long viremic phase before causing skin disease while HSV
infects directly at the mucosal level where disease appears, such
as the genitalia and the oral cavity. Viremia is also thought to be
rare in HSV infections. On the other hand inﬂuenza, which is
vaccine-preventable, has a very short incubation period and also
directly infects the organ system involved in disease.
Additional factors may be involved. HSV appears to have more
fully developed strategies for immune evasion than VZV (Johnson
et al., 2011). Prolonged immunity is the rule following varicella,
with reinfections being unusual. In contrast, reinfections with
HSV are not uncommon, and frequent subclinical shedding of
infectious virus occurs (Johnston et al., 2011). The protective
immune responses for HSV are not well understood, although it is
known that persistent inﬁltrates of CD4þ and CD8þ T cells
directed towards HSV are present in the mucosa and at nerve
endings (Johnston et al., 2011; Zhu et al., 2007). Almost constant
genital shedding of HSV 2 suggests that natural immunity to HSV
is not very effective, at least in some individuals. In contrast, an
immune correlate, the FAMA assay, indicates whether an indivi-
dual is immune to varicella or not (Michalik et al., 2008).
Interestingly, while there are many animal models of HSV infec-
tions, varicella vaccine was developed in the absence of such a
model. Possibly because immunity to viruses may be mediated
differently in humans than in small laboratory animals, which
have not evolved adaptive responses to HSV such as immune
evasion, over the millennia as have humans, animal models may
complicate vaccine development rather than simplify it.
Outsmarting HSV has not proven to be an easy task. But since
VZV vaccination seems to have improved on Mother Nature,
perhaps this can be accomplished for HSV as well. Certainly there
are many candidate vaccines for testing, and these might be used,
possibly even in combinations, to produce strong immune
responses to HSV. Reasoning from VZV vaccines, the phenomenon
of latency and reactivation can be improved from the human
perspective by vaccines. While sterilizing immunity is the ideal,
some degree of immune failure is likely but should not in itself
preclude vaccination against HSV. Decreasing viral transmission
of HSV along with herd immunity, even if imperfect, would seem
to be the most important goals of vaccination. Mathematical
models suggest that even non-sterilizing vaccines may decrease
viral shedding and transmission of HSV 2 (Garnett et al., 2004).
A successful vaccine should protect both mucosal and epidermal
sites, and ideally not infect neurons (Johnston et al., 2011).
While signiﬁcant protective immune responses against HSV
are not yet fully identiﬁed, it is clear that innate and adaptive
immunity play roles in control of HSV infections and therefore
could be manipulated by vaccination. For example, individuals
have been identiﬁed in HSV discordant relationships who appear
A.A. Gershon / Virology 435 (2013) 29–3634to resist HSV infection, likely due to T cell responses to certain
immediate early viral proteins (Posavad et al., 2010).
While antivirals are important for disease control, they cannot
substitute for a vaccine; they are useful however when vaccines
are not as protective as one would like them to be or if there are
adverse events that require therapy. Antivirals can certainly play
an adjunct role to vaccination, as they have for varicella vaccine.
Why is it important to develop vaccines against HSV? Most
children and adults who are infected with HSV manifest self-
limited infections. On the other hand, HSV causes life-threatening
disease including neonatal infections, encephalitis, and eczema
herpeticum, as well as sight-threatening keratitis. Host immune
defenses such as cytotoxic T cells and natural killer (NK) cells are
not fully matured in the neonate, which may explain the inability
of infected newborns to contain HSV infections (Corey and Wald,
2009; Kimberlin and Whitley, 2005). While HSV encephalitis and
neonatal HSV can be treated with antiviral drugs, these are not
always completely effective and survivors often have signiﬁcant
morbidity (Corey and Wald, 2009; Kimberlin and Whitley, 2005).
Patients with abnormalities in innate immunity are pre-
disposed to develop severe or persistent HSV infections. HSV
encephalitis has been associated with genetic abnormalities
involving toll like receptors (TLR3), UNC93B1, and STAT1 signal-
ing in children (Casanova et al., 2011; Casrouge et al., 2006; Zhang
et al., 2007). In addition, single nucleotide polymorphisms (SNPs)
in TLR2 in humans have been associated with high levels of HSV
mucosal shedding, and low interferon-alpha responses (Bochud
et al., 2007). One can speculate that by improving adaptive immune
responses through a vaccine, deﬁciencies in innate immunity might
be overcome.
It is possible that effective vaccines against HSV might also
beneﬁt certain other individuals, including immunocompromised
patients. Varicella vaccine was successfully used to prevent chick-
enpox in children with underlying leukemia in the 1980 s, before
herd immunity had developed in the United States due to wide-
spread vaccination of healthy children and adults (Gershon et al.,
1984b). An inactivated VZV vaccine was used to protect immuno-
compromised persons against HZ (Hata et al., 2002). Vaccination
against HSV might also offer indirect protection against HIV infec-
tion, because the risk of HIV-1 infection is increased by a factor of
3 in HSV- 2 seropositives (Freeman et al., 2006).
It is beyond the scope of this review to delineate the many
candidate vaccines against HSV. Sufﬁce it to say that these consist
of live attenuated vaccines with various mutations such as
deletion of immune evasion genes, subunit adjuvanted vaccines,
DNA vaccines that encode various HSV proteins, and replication
incompetent vaccines. Ideally it would be best to vaccinate
against both HSV 1 and HSV 2, even though HSV 2 seems to
protect partially against HSV 1. Based upon experience with other
viral vaccines, live attenuated viruses seem to be the most
dependable to stimulate long lasting immunity. Immunization
of children and adolescents before onset of sexual activity would
seem appropriate.
In summary, vaccination against HSV is a worthwhile goal, and
one that with available molecular virologic techniques seems
achievable.References
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